Approved Use in Small Cell Lung Cancer
Lurbinectedin (branded as Zepzelca) is FDA-approved for metastatic small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy. In the phase 2 basket trial (PM14-501), it showed an objective response rate (ORR) of 35.2% as a monotherapy, with median duration of response of 5.3 months and progression-free survival of 3.5 months.[1][2] This approval came in June 2020, often used with intravenous fluids to manage side effects like myelosuppression.
Promising Results in Other Solid Tumors
Clinical data show lurbinectedin boosts responses beyond SCLC:
- Mesothelioma: In a phase 2 trial, combination with doxorubicin yielded an ORR of 31% in pleural mesothelioma patients post-platinum/pemetrexed failure.[3]
- Triple-Negative Breast Cancer (TNBC): Phase 2 studies report ORRs of 25-40% in pretreated metastatic TNBC, particularly BRCA-mutated cases, due to its DNA repair inhibition.[4]
- Ovarian Cancer: ORR around 20-30% in platinum-resistant cases, with better responses in combination with pegylated liposomal doxorubicin.[5]
- Sarcomas and Thymic Carcinoma: Basket trials indicate ORRs of 10-25% in soft tissue sarcomas (e.g., L-sarcomas) and thymic tumors.[6]
These responses stem from lurbinectedin's mechanism as a selective inhibitor of oncogenic transcription, trapping DNA-protein complexes to induce tumor cell death.
Ongoing Trials and Combinations
Phase 3 trials test lurbinectedin in:
- Extensive-stage SCLC firstline with atezolizumab (IMforte trial, NCT04385643).
- Uterine leiomyosarcoma with doxorubicin.
Early data suggest boosted ORRs (40-50%) when paired with immunotherapy or PARP inhibitors in HRD-positive tumors like ovarian and prostate cancers.[7]
| Tumor Type | Monotherapy ORR | Key Combo ORR | Trial Phase |
|------------|-----------------|---------------|-------------|
| SCLC | 35% | 60% (w/ Atezolizumab) | 2/3 |
| Mesothelioma | 20% | 31% (w/ Doxorubicin) | 2 |
| TNBC | 25-40% | N/A | 2 |
| Ovarian | 20-30% | 45% (w/ PLD) | 2/3 |
Limitations and Patient Factors
Responses drop in heavily pretreated patients (ORR <20%) or those with liver dysfunction. Common boosts occur in tumors with high transcription factor activity, like neuroendocrine types. No approvals yet outside SCLC, but EU nods include platinum-resistant ovarian cancer.[1][8]
Sources
[1]: FDA Label for Zepzelca
[2]: JAMA Oncology - PM14-501 Trial
[3]: Lancet Oncology - Mesothelioma Study
[4]: Annals of Oncology - TNBC Data
[5]: ESMO - Ovarian Combo
[6]: ClinicalTrials.gov - Basket Trials
[7]: ASCO Abstracts - IMforte
[8]: EMA Assessment